ストックスクリーナーアプリを入手
0.00
100.00%
-14.49
Amicus Therapeutics Inc (FOLD) 最新ニュース
Amicus Therapeutics Reports 2025 Financial Results, Merger With BioMarin, and Key Pipeline Updates - Minichart
BioMarin (BMRN) details Amicus 2025 results and $14.50-per-share merger terms - Stock Titan
Our Origin Story - BioMarin Pharmaceutical
Amicus Therapeutics Inc (FOLD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amicus Therapeutics Inc (FOLD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Amicus Therapeutics (FOLD) Holds Steady at $14.49 Amid Consolidation PhaseIntraday Trade Ideas - dars.gov.et
Amicus Therapeutics Inc (FOLD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Amicus Therapeutics Q2 2025 Earnings Preview - MSN
Amicus Therapeutics Stock (US03152W1099): valuation picture in focus for biotech name FOLD - ad-hoc-news.de
May layoffs hit nearly 7,000, with most cuts from Takeda, BioNTech - BioSpace
BioMarin Pharmaceutical's Revenue Guidance Boost Reflects Pipeline Progress and Acquisition GrowthPost-Announcement Reaction - DonanımHaber
Amicus Therapeutics Holds Steady at $14.49 as Key Levels Define Trading RangeAAII Bullish - DonanımHaber
John Paulson’s fund initiates Amicus Therapeutics position, dumps SOLS among Q1 moves - MSN
Amicus Therapeutics (FOLD) Holds Steady Near Support as Biotech Sector Waits for CatalystEarnings Breakout Stocks - dars.gov.et
Amicus Therapeutics stock (US03152W1099): analysts see limited upside after strong run - AD HOC NEWS
Are Amicus Therapeutics (FOLD) and Autoliv (ALV) Overlooked Opportunities - Kavout
Paulson & Co. Acquires Amicus Therapeutics (FOLD) and Exits Solstice Advanced Materials (SOLS) - GuruFocus
Barclays holds 17.8M Amicus shares (NASDAQ: FOLD), 5.65% stake - Stock Titan
Amicus Therapeutics stock (US03152W1099): Biotech focused on rare diseases - AD HOC NEWS
FOLD SEC FilingsAmicus Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Goldman Sachs (FOLD) discloses 16.78M shares, 5.3% ownership (Schedule 13G) - Stock Titan
Fabry Disease Treatment Market to Reach USD 3,530.5 Million - openPR.com
BioMarin Q1 earnings miss, sales beat, '26 revenue guidance raised - MSN
Amicus Therapeutics (Delisted) | SCHEDULE 13G: Others - Moomoo
UBS Group-affiliated funds hold 17.14M shares in Amicus Therapeutics (NASDAQ: FOLD) - Stock Titan
[15-12G] AMICUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Which Is a Better Investment, AnaptysBio, Inc. or Amicus Therapeutics, Inc. Stock? - AAII
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition (NASDAQ:BMRN) - Seeking Alpha
BioMarin acquires Amicus Therapeutics for $4.8bn - MSN
MSN Money - MSN
BioMarin to buy rare disease drugmaker Amicus Therapeutics for $4.8B - MSN
BioMarin beats estimates, raises guidance on Amicus deal By Investing.com - Investing.com South Africa
BioMarin beats estimates, raises guidance on Amicus deal - Investing.com
BioMarin Reports First Quarter 2026 Financial and Operating Results - Santa Maria Times
UBS Group AG Grows Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
CM Management LLC Has $5.27 Million Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin Amicus Deal Expands Rare Disease Reach And Adds Kidney Asset - Sahm
Glazer Capital (FOLD) reports zero holdings after falling below 5% stake - Stock Titan
Pictet Asset Management Holding SA Trims Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Decreases Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin Closes Amicus Deal As FOLD Delists And Indices Adjust - Sahm
[EFFECT] AMICUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Amicus Therapeutics (FOLD) Expected to Announce Earnings on Thursday - MarketBeat
0.72%
大文字化:
|
ボリューム (24 時間):